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Fibrotic response in fibroblasts from congenital disorders of
glycosylation
Abstract
Congenital disorders of glycosylation (CDG) are characterized by a generalized underglycosylation of
proteins. CDG is associated with multiple symptoms like psychomotor retardation, hypotonia, hormonal
disturbances, liver fibrosis and coagulopathies. The molecular basis of these symptoms is poorly
understood considering the large extent of affected glycoproteins. To better understanding the cellular
responses to protein underglycosylation in CDG, we have investigated the differences in gene
expression between healthy control and CDG fibroblasts by transcriptome comparison. This analysis
revealed a strong induction of several genes encoding components of the extracellular matrix, such as
collagens, COMP, IGFBP5 and biglycan. The extent of this response was confirmed at the protein level
by showing increased production of collagen type-I for example. This fibrotic response of CDG
fibroblasts was not paralleled by a differentiation to myofibroblasts and by increased TGFβ signaling.
We could show that the addition of recombinant IGFBP5, one of the induced proteins in CDG, to
healthy control fibroblasts increased the production of collagen type-I to levels similar to those found in
CDG fibroblasts. The fibrotic response identified in CDG fibroblasts may account for the elevated tissue
fibrosis, which is often encountered in CDG patients.
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Introduction 
N-linked glycosylation is a widespread and essential modification of proteins in 
eukaryotes. Oligosaccharides are first assembled on the lipid-carrier dolichol and 
then transferred co-translationally to asparagine residues of nascent glycoproteins 
[1,2]. Loss or gain of individual N-glycosylation sites can alter the stability and 
function of the corresponding glycoprotein. Along this line, some forms of 
metachromatic leukodystrophy [3], thrombophilia [4,5], and 1-antitrypsin 
deficiency [6] are caused by mutations leading to the loss of N-glycosylation sites. 
Alternatively, the gain of a N-glycosylation site in the IFNR2 protein has been 
shown to abolish IFN response in a form of immunodeficiency [7]. By contrast, 
defects of lipid-linked oligosaccharide (LLO) biosynthesis cause generalized 
decreased N-glycosylation sites occupancy due to limited availability of complete 
LLO in the endoplasmic reticulum (ER) leading to pleiotropic changes. In addition, 
the structure of N-glycans on glycoproteins can be defective when glycan processing 
and elongation steps are altered in the secretory pathway.  Both forms of N-
glycosylation defects belong to the family of congenital disorders of glycosylation 
(CDG) [8-10]. Considering the broad impact of glycosylation on protein functions, 
CDG are associated with developmental delay, malformations and multiple organ 
dysfunctions [11]. While symptoms like coagulopathies, gastrointestinal bleeding 
and protein-losing enteropathy are seen in specific types of CDG, hepatic and tissue 
fibrosis is a common feature observed in several forms of CDG. In some CDG cases, 
skin abnormalities such as cutis laxa [12] and ichthyosis [13] have also been 
described. However, the molecular mechanisms underlying most CDG symptoms 
are largely unclear [14].  
Alterations of N-glycosylation affect multiple signaling pathways by altering the 
stability of membrane proteins or the signaling ability of membrane receptors [15]. 
For example, the loss of specific N-glycan branches increases the endocytosis of the 
glucose transporter GLUT2 [16] and of several cytokine receptors [17]. Similarly, 
changes of N-glycan core fucosylation inhibits TGF signaling, which leads to 
decreased production of extracellular matrix (ECM) proteins and to lung emphysema 
in 1-6 fucosyltransferase (FUT8) deficient mice [18]. Increased core fucosylation of 
N-glycans has also been observed in CDG cases with defects in the LLO synthesis 
pathway [19,20]. Whereas the cytokine TGF is a central regulator of the production 
of ECM proteins [21], additional proteins, such as factors of the CCN family [22] and 
the matricellular protein SPARC [23], have been reported to also mediate a 
profibrotic effect. 
To gain insight into the pathogenesis of CDG manifestations, we have investigated 
the gene expression signature of CDG fibroblasts from patients with defects in the 
LLO synthesis pathway namely in DPM1 dolichylphosphate mannose synthase 
(DPM1-CDG, CDG-Ie) [24,25], ALG12 mannosyltransferase (ALG12-CDG, CDG-Ig) 
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[26-28] and ALG6 glucosyltransferase (ALG6-CDG, CDG-Ic) [29]. These three gene 
defects lead to the specific accumulation of the distinct LLO structures dolichyl-
pyrophosphate-GlcNAc2Man5, dolichyl-pyrophosphate-GlcNAc2Man7 and dolichyl-
pyrophosphate-GlcNAc2Man9, respectively. Our study demonstrated an increased 
expression of several ECM proteins in CDG and pointed to the involvement of 
insulin-like growth factor-binding protein (IGFBP) 5 in the mediation of this fibrotic 
response. 
 
Materials and Methods 
Cell culture - Primary fibroblasts from three healthy control subjects and from nine 
CDG patients were isolated from a skin biopsy and were grown in DMEM 
(Invitrogen) with 4.5 g/l glucose and 10% fetal calf serum. The CDG cells used have 
mutations in the dolichylphosphate mannose synthase (R92G/del628c; S257P/S257P; 
R92G/13-bp del), ALG12 mannosyltransferase (A81T/A81T; T67M/R146Q; 
G101R/G101R) and ALG6 glucosyltransferase (A333V/A333V; S478P/S478P; 
A333/IVS3+5G>A) genes. 
Collagen determination – Collagen concentration was determined using the Sircol 
assays (Biocolor) according to the manufacturer instructions. Fibroblasts (2 x 106) 
were digested overnight in 100 l of pepsin (0.1 mg/ml, Sigma) in Hanks Balanced 
Salt Solution, pH 7.0. Collagen was precipitated by the Sircol dye reagent and 
collected by centrifugation while the unbound dye was removed by adding 0.5 M 
NaOH. The absorption at 540 nm was measured by spectrophotometry. 
Oligonucleotide arrays - Total RNA was isolated from fibroblast cultures and reverse 
transcribed as described previously [30]. cDNA samples were purified by phenol-
chloroform extraction and 5 l were in vitro transcribed in presence of biotin-labeled 
nucleotides using the High Yield Transcription kit (ENZO Diagnostic USA). Biotin-
labeled cRNA samples (15 g) were fragmented at 95 °C in 40 mM Tris-acetate, 100 
mM K-acetate, 30 mM Mg- acetate and mixed in 300 l of hybridization buffer 
containing a hybridization control mix, including reference genes (GAPDH, ACO7), 
spike controls (BIOB, BIOC, CREX, BIODN) and proprietary Affymetrix B2 
oligonucleotides, 0.1 mg/ml herring sperm DNA and 0.5 mg/ml acetylated bovine 
serum albumin in 2-(4-morpholino)-ethane sulfonic acid (MES) buffer, pH 6.7. HG-
U133A gene chips (Affymetrix) were incubated with the cRNA samples for 16 h at 45 
°C, and washed using an Affymetrix Fluidics Station 400. cRNA bound to the 
oligonucleotide arrays was stained with phycoerythrin-streptavidin and with biotin-
labeled anti-streptavidin antibody. The fluorescent signal emitted by the labeled 
targets was measured using a Gene-Array scanner G2500 (Agilent). The array data is 
available at the GEO repository under accession number GSE8440. 
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Statistical Analysis - Raw data processing was performed using the Affymetrix 
Microarray Suite Ver. 5.0 (MAS5) software. After hybridization and scanning, probe 
cell intensities were calculated and summarized for the respective probe sets using 
MAS5 software [31]. The trimmed mean of each chip was normalized to a target 
intensity of 500 as recommended by Affymetrix. Scaling factors and appropriate 
numbers of present calls ( ≥ 50%) were calculated by application of a signed-rank call 
algorithm [32]. Statistical parametric methods based on the comparisons between the 
triplicates of each condition were applied. The Cross-Gene Error Model from the 
Gene Spring software 5.1. (Silicongenetics, 2003) was applied to filter unreliable 
genes and unequal variance t-test for two, or ANOVA for more than two groups, 
were applied to detect differentially expressed genes. The False Discovery Rate was 
applied [33] to reduce the number of false positive genes. 
Immunofluorescence microscopy - Cells were fixed in 3.5 % paraformaldehyde for 10 
min and permeabilized with 0.1% saponin in phosphate buffered saline (PBS). Cells 
were incubated with primary antibodies for 1 h in 0.1% saponin in PBS. After 
washing twice with PBS, the cells were incubated with Alexa488-conjugated 
secondary antibody in 0.1% saponin in PBS for 30 min. Immunofluorescence images 
were taken by an Axiovert 200M microscope (Zeiss) using the Axiovision 3.0 
software (Zeiss). The antibodies used were specific to collagen type-I (Sigma, clone 
COL-1), -smooth muscle actin (Sigma, clone 1A4), Smad4 (Santa Cruz). 
Western blot analysis - Proteins from the postnuclear supernatants of fibroblast cells 
were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes 
according to Towbin et al. [34]. Membranes were incubated over night with primary 
antibodies against IGFBP5 (Upstate), COMP (Kamya), PSG1 (BD Biosciences, clone 
IID10), endoglin (BD Biosciences, clone 35), -tubulin (Sigma, clone SAP.4G5), 
pSMAD2 (Cell signalling). After washing in Tris-bufferd saline with 0.1% Tween-20, 
membranes were incubated with a horseradish peroxidase conjugated secondary 
antibody (Sigma) for 1.5 h and signals were detected by chemiluminescence (Pierce). 
IGFBP5 and TGF treatment - Fibroblasts from CDG patients and healthy controls 
were seeded at a density of 106 cells in 10 cm plates 24 h prior treatment with 10 
ng/ml TGF (Sigma). Treatment with TGF was carried out for 36 h prior harvesting 
for Sircol assay. For the TGF sensitivity experiment, 0.2x106 fibroblasts were seeded 
in 6-well plates overnight. Medium was exchanged with serum free medium for 10 
min before adding TGFin different concentrations for 30 min to the cells. The 
reaction was stopped by washing the cells with ice cold PBS and cells were harvested 
and lyzed for Western blot analysis. For IGFBP5 treatment, 0.2x106 healthy control 
fibroblasts were plated in 6-wells on cover slips. Recombinant human IGFBP5 was 
given to the medium in the concentrations 0, 0.25, 0.75, and 1.5 g/ml for 60 h prior 
to immunofluorescence. 
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Results 
To appreciate the range of cellular responses linked to glycosylation disorders, we 
have analyzed the global gene transcription profile of ALG6-CDG, DPM1-CDG and 
ALG12-CDG fibroblasts by oligonucleotide array hybridization [30]. Genes with 
similar expression profiles in the different CDG were resolved by hierarchical 
clustering. This analysis showed that multiple genes encoding components of the 
extracellular matrix were highly induced in the three forms of CDG (Fig. 1). The 
induced genes comprised collagen genes such as COL1A1, COL4A1, COL4A2, 
COL5A1, COL11A1 and COL18A1, cartilage oligomeric protein (COMP), biglycan 
(BGN), hyaluronan and proteoglycan link protein 1 (HAPLN1), fibronectin (FN), 
tenascin-C (TNC) and nidogen-1 (NID1) in particular (Table 1). Matrix 
metalloproteinases, like the BMP1 collagenase and the MMP3 proteoglycanase were 
also among the genes significantly overexpressed in CDG fibroblasts. Another group 
of ECM genes induced in CDG fibroblasts were four members of the pregnancy 
specific glycoproteins (PSG). PSG are closely related to the carcinoembryonic antigen 
family and are mainly transcribed in the placenta [35], although they are also 
expressed in other tissues according to the UniGene's EST Profile Viewer [36]. 
Components of the TGF pathway were also found among the list of genes induced 
in CDG. The TGF and TGF receptor-I mRNAs were slightly elevated in CDG 
fibroblasts whereas endoglin, a co-receptor for TGF [37], was induced between 1.9- 
and 3.6-fold in CDG fibroblasts (Table 1).  Members of the Wnt/-catenin signaling 
pathway such as the Wnt2 signaling protein (WNT2), the Wnt-1 inducible signaling 
pathway protein (WISP-1) as well as the Sox11 transcription factor were 
overexpressed  above 2-fold in CDG fibroblasts. 
To validate the up-regulation of ECM components at the protein level, we first 
measured collagen production in fibroblasts. Using the Sircol dye assay, we detected 
elevated collagen concentrations in all CDG fibroblasts tested (Fig. 2A). The 
increased collagen production was confirmed by immunofluorescence analysis of 
fibroblasts using an antibody to collagen type-I (Fig. 2B). The induction of ECM 
components in CDG was also confirmed by Western blot analysis of the proteins 
IGFBP5, COMP, endoglin and PSG1 (Fig. 3). Whereas the production of ECM 
proteins by fibroblasts is often associated to myofibroblastic differentiation, such a 
phenotype was not observed in CDG fibroblasts, as assessed by the low level of the 
myofibroblast marker protein -smooth muscle actin [38] (data not shown). 
The cytokine TGFis a prominent stimulus of ECM expression [21]. To examine 
whether CDG fibroblasts are more sensitive to TGF than control fibroblasts, we 
treated CDG and control fibroblasts with the profibrotic cytokine TGF. The levels of 
collagen production were strongly increased in all treated cells with the exception of 
DPM1-CDG fibroblasts (Fig. 4). We also investigated whether CDG fibroblasts are 
more sensitive to TGF, considering the increased expression of endoglin in those 
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cells. The levels of SMAD2 phosphorylation were measured in control and CDG 
fibroblasts stimulated with increasing amounts of TGF. This titration showed no 
clear difference of SMAD2 phosphorylation between control and CDG fibroblasts 
(Fig. 5). Finally, we investigated the activation of the TGF pathway by examining 
the level of SMAD4 nuclear localization in CDG and control fibroblasts. Also this 
parameter did not differ significantly between the cells examined (data not shown), 
indicating that the TGFpathway did not account for the increased ECM protein 
expression in CDG fibroblasts.  
The observed increased expression of IGFBP5 in CDG was unexpected. The IGFBP5 
protein has been associated to pulmonary fibrosis, where IGFBP5 has been shown to 
stimulate the production of ECM proteins by activating fibroblasts [39]. Therefore, 
we did test whether the increased IGFBP5 expression in CDG fibroblasts could be 
related to the increased production of ECM components in these cells. We incubated 
control fibroblasts with recombinant IGFBP5 at increasing concentrations. The 
addition of IGFBP5 at 0.25 g/ml was sufficient to increase the level of collagen 
production after 2 days, whereas this effect was highest at an IGFBP5 concentration 
of 1.5 g/ml (Fig. 6). This effect was similar to that obtained when stimulating 
fibroblasts with 10 ng/ml of TGF. 
Overall we showed that decreased N-glycosylation site occupancy parallels the 
expression of ECM genes. The unchanged TGF signaling pathway in control and 
patient cells pointed to a different molecular mechanism of ECM induction. The fact 
that it was possible to increase the collagen expression by recombinant IGFBP5 in 
controls showed that this protein is probably involved in the induction of ECM gene 
expression in CDG. 
 
Discussion 
N-linked glycosylation is required for the proper function of many glycoproteins. 
The stability of membrane proteins is depending on the branching of N-glycans and 
the degree of N-glycosylation site occupancy [15]. CDG with defects of LLO 
synthesis pathway leads to unoccupied N-glycosylation sites. To address the 
physiological processes and molecular pathways altered by deficient N-glycosylation 
site occupancy, a global gene transcription array study was performed in different 
CDG subtypes. In an earlier study, we could show that the unfolded protein 
response and amino acid metabolism were induced in CDG fibroblasts [30]. In the 
present work, we have shown that pro-fibrotic genes were also induced in CDG 
fibroblasts. This observation fits with the observation of tissue fibrosis in some types 
of CDG [40-43].   
The over-expression of COMP in CDG fibroblasts may be related to the interaction of 
this protein with some types of collagen, such as collagen type-I, which was also 
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over-expressed in CDG fibroblasts. COMP expression has been shown to be TGF-
dependent in systemic sclerosis [44], atherosclerotic lesions [45] and chronic 
pancreatitis [46]. Altered folding and secretion of COMP causes 
pseudoachondroplasia [47], but changes of COMP expression have not been 
associated with pathogenic phenotypes yet. 
Identifying the underlying molecular reasons for the up-regulation of ECM genes can 
provide clues for potential therapeutic targets. We first tested the TGF signaling 
pathway as the possible actor. Although some members of the TGF signaling 
pathway were among the induced genes, the whole pathway was not induced in 
CDG and also the sensitivity of the pathway was not altered. Therefore, a second 
agent, IGFBP5 that is less well characterized than TGFβ was investigated as a booster 
of ECM gene expression (Fig. 5). Stimulation of control fibroblasts with IGFBP5 
indeed showed a similar effect of collagen induction as the stimulation with TGF. 
This observation could be extended to CDG fibroblasts (Fig. 6). The IGFBP5 protein 
has previously been associated to fibrosis. IGFBP5 is over-expressed in systemic 
sclerosis fibroblasts and in idiopathic pulmonary fibrosis [39,48]. Adenoviral 
expression of IGFBP5 in skin of mice induced fibrosis with increased dermal 
thickness and increased deposition of collagen and fibronectin [49]. IGFBP5 is 
proposed to be a central player in the initiation of fibrosis and in the response to 
injury [49,50]. However, the molecular basis of IGFBP5-mediated fibrosis is not yet 
completely understood. Members of the family of the IGFBPs bind with high affinity 
to the insulin-like growth factors (IGF)-I and –II and therefore regulate the activity of 
the IGF-axis either positively or negatively [51,52]. The IGF axis is a key regulator of 
cellular growth, differentiation and apoptosis processes [53]. Probably the more 
relevant mechanism for the ECM induction by IGFBP5 is the ability of IGFBP5 to 
bind to ECM components like collagens, fibronectin and heparan sulfates [54,55]. 
This binding may protect the ECM proteins from degradation and over-expression of 
IGFBP5 causes the deposit of big amounts of ECM proteins. The binding of IGFBP5 
to ECM proteins also deprives the pool of free IGFBP5 that can bind IGFs and 
therefore has an influence on the activity of the IGF pathway [49,56].  
The reasons why protein underglycosylation goes along with the up-regulation of 
IGFBP5 expression are unknown and we can only speculate. Receptor activities are 
influenced by altered glycosylation. Besides the TGF signaling pathway also 
cytokine receptors are influenced by glycosylation. The overexpression of 1,6-N-
acetylglucosaminyltransferaseV (MGAT5), which initiates the fourth branch of N-
glycans, is leading to a sensitization of the cells to cytokines due to retarded 
endocytosis of the receptors [17]. This sensitization was depending on the branching 
of the N-glycan, hence the MGAT5 expression level, but also on the number of total 
N-glycans. Therefore, underglycosylation due to a deficient LLO synthesis pathway 
may alter cytokine response and thus the downstream targets as for example 
IGFBP5.  
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The correlation between the underglycosylation of proteins in CDG patients and the 
observed symptoms are poorly understood. Appreciating and understanding the 
mechanisms underlying the symptoms represent a first step towards the 
identification of potential targets for therapeutic approaches.  Hepatic fibrosis creates 
a long-term risk for CDG patients and represents a negative prognostic factor for the 
application of mannose therapy in CDG-Ib [42].  By comparison, fibrotic changes in 
systemic sclerosis fibroblasts reflect a generalized deposition of ECM proteins also in 
internal organs [57]. Although TGF, integrin/ILK and Wnt/-catenin pathways 
represent  the three major signaling pathways driving tissue fibrosis, ECM 
deposition can be induced by different  stimuli [58]. We have identified IGFBP5 as a 
potential inducer of collagen type-I in CDG-fibroblasts.  Future efforts in 
characterizing the IGFBP5-dependent fibrotic phenotype will help to identify the fine 
tuning of molecules driving liver fibrosis in CDG and to develop disease-specific 
therapeutic targets.  
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Figure legends 
Figure 1. Gene clustering analysis of ECM genes. The colors indicate the expression 
levels relative to the median of all measurements for the gene throughout all the 
samples analyzed. Red means up-regulated and green means down-regulated in 
comparison to the median. The blue arrows mark collagen genes and the red arrows 
other ECM genes. 
  
Figure 2. Collagen type-I levels in CDG and healthy control fibroblasts. A. Total 
collagen in fibroblasts measured by Sircol assay, shown are averages and SEM of 
three assays (A). Immunofluorescence staining of collagen type-I in healthy control 
fibroblasts (B), ALG6-CDG fibroblasts (C), DPM1-CDG fibroblasts (D) and ALG12-
CDG fibroblasts (E). 
 
Figure 3. Validation of up-regulated genes at the protein level in control and CDG 
patient fibroblasts. Western blot analysis was performed with antibodies against 
IGFBP5, COMP, endoglin, and PSG1. -tubulin was used as the loading control. 
Molecular weights in kDa are indicated on the left. 
 
Figure 4. Induction of collagen expression in CDG and healthy control fibroblasts by 
TGF treatment. Sircol assay was performed from untreated (white bars) and TGF 
stimulated cells (black bars).  Shown are averages and SEM of three assays.  
 
Figure 5. Sensitivity of CDG and healthy control fibroblasts to TGF. Fibroblasts 
from healthy controls and CDG patients were treated with TGF for 30 min. Western 
blot analysis was performed with an antibody to phosphorylated SMAD2. 
 
Figure 6. Collagen type-I expression in healthy control fibroblasts after IGFBP5 
treatment. Healthy control cells were treated with 0 (A), 0.25 (B), 0.75 (C), 1.5 (D) 
g/ml of recombinant IGFBP5 and immunofluorescence was performed with a 
collagen type-I antibody.  
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Table 1. mRNA levels of ECM genes in CDG fibroblasts. The values represent 
averages of independent measures and indicate the fold-induction compared to the 
mRNA levels measured in control cells. Fibroblasts from 4 ALG6-CDG, 3 DPM1-
CDG and 2 ALG12-CDG cases were investigated. The expression values obtained in 
the CDG fibroblasts were significantly different from the control values (one-way 
ANOVA-test, p < 0.05).   
Gene Symbol Accession 
ALG6-
CDG 
DPM1-
CDG 
ALG12-
CDG 
Collagen type 1, alpha 1 COL1A1 BC036531 3.6 7.2 5.5 
Collagen type 4, alpha 1 COL4A1 NM_001845 1.3 2.6 2.3 
Collagen type 4, alpha 2 COL4A2 NM_001846 1.3 2.0 2,9 
Collagen type 5, alpha 1 COL5A1 NM_000093 1.8 2.1 1.5 
Collagen type 11, alpha 1 COL11A1 NM_001854 3.3 10.3 11.9 
Collagen type 18, alpha 1 COL18A1 NM_030582 1.5 2.1 2.0 
Cartilage oligomeric matrix protein COMP NM_000095 18.4 21.1 8.0 
Hyaluronan and proteoglycan link protein-1 HAPLN1 NM_001884 5.7 2.1 17.2 
Biglycan BGN NM_001711 4.4 5.1 2.8 
Fibronectin FN1 NM_212482 1.9 3.8 2.8 
Thrombospondin-1 THBS1 AI812030 1.4 4.4 1.8 
Tenascin-C TNC NM_002160 2.4 1.6 1.0 
Nidogen-1 NID1 NM_002508 1.7 2.2 1.0 
Tissue factor pathway inhibitor-2 TFPI2 NM_006528 3.2 2.2 0.3 
EGF-like repeats and discoidin I-like 
domains-3 
EDIL3 NM_005711 4.4 6.1 7.7 
Bone morphogenic protein-1 BMP1 NM_001199 2.1 2.0 2.1 
Matrix metalloproteinase-3 MMP3 NM_002422 1.3 3.6 1.7 
Pregnancy specific glycoprotein-1 PSG1 NM_006905 6.2 5.0 5.7 
Pregnancy specific glycoprotein-4 PSG4 NM_002780 5.3 4.0 5.4 
Pregnancy specific glycoprotein-6 PSG6 NM_002782 1.4 1.2 1.4 
Pregnancy specific glycoprotein-7 PSG7 NM_002783 6.6 7.3 7.0 
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Insulin-like growth factor binding protein-5 IGFBP5 R73554 8.1 3.0 1.5 
Neuropilin-2 NRP2 NM_201266 1.7 3.0 2.2 
Interleukin-8 IL8 NM_000584 2.4 5.5 1.4 
Transforming growth factor  TGFB1 M60316 1.2 1.9 2.0 
TGF receptor-1 TGFBR1 NM_004612 1.6 1.9 1.3 
Endoglin ENG NM_000118 1.9 3.6 2.7 
Homolog of mothers against 
decapentaplegic, 7 
SMAD7 NM_005904 1.4 1.9 0.8 
Wingless-type MMTV integration site family, 
member 2 
WNT2 NM_003391 6.1 2.3 2.5 
WNT1-inducible signaling pathway protein 1 WISP1 AB034725 5.5 7.0 5.0 
SRY-box 11 SOX11 AB028641 6.3 5.6 5.4 
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